Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab SC Open-Label Extension in Severe Eosinophilic Asthma
NCT03052725Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of reslizumab in eosinophilic asthma (EA), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Participants With Treatment-Emergent Adverse Events. Started Mar 2017; status: terminated.
02
Drugs
reslizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT03052725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052725.